Lipid Metabolism Practice Questions

Q: A 55-year-old male with a 15-year history of type 2 diabetes mellitus presents unconscious. His random blood sugar is 268 mg/dl, and blood and urine samples confirm the presence of ketone bodies. Which of the following would NOT be found in the urine sample?

Glycerol 3-phosphate. ### Explanation **Correct Option: D. Glycerol 3-phosphate** **Reasoning:** The patient is presenting with **Diabetic Ketoacidosis (DKA)**, characterized by hyperglycemia and the presence of ketone bodies. Ketogenesis occurs in the liver mitochondria when there is a high rate of fatty acid oxidation. The three primary ketone bodies produced are **Acetoacetate**, **β-hydroxybutyrate**, and **Acetone**. **Glycerol 3-phosphate** is an intermediate in glycolysis and triglyceride synthesis, not a ketone body. In the context of DKA, while lipolysis in adipose tissue releases glycerol into the blood, it is converted to glycerol 3-phosphate primarily within the **liver** (via glycerol kinase) to serve as a substrate for gluconeogenesis. It is an intracellular metabolite and is **not excreted in the urine.** **Analysis of Incorrect Options:** * **A & B (β-hydroxybutyrate and Acetoacetate):** These are the two acidic ketone bodies produced by the liver. They are filtered by the kidney and appear in the urine (ketonuria) when their blood concentration exceeds the renal threshold. * **C (Acetone):** This is a non-metabolizable side product formed by the spontaneous decarboxylation of acetoacetate. It is excreted through the lungs (giving the characteristic "fruity breath") and also in the urine. **NEET-PG High-Yield Pearls:** * **Rothera’s Test:** Detects **Acetoacetate** and **Acetone** in urine (it does *not* detect β-hydroxybutyrate). * **Ratio in DKA:** β-hydroxybutyrate is usually the predominant ketone body in DKA due to the high NADH/NAD+ ratio. * **Key Enzyme:** **HMG-CoA Synthase** is the rate-limiting enzyme for ketogenesis. * **Utilization:** The liver produces ketone bodies but cannot use them because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase).

Q: Which organ is not directly involved in cholesterol transport?

Kidney. **Explanation:** The transport of cholesterol is primarily mediated by the **Exogenous** and **Endogenous** lipoprotein pathways. The **Kidney** is the correct answer because it does not play a direct role in the synthesis, packaging, or systemic transport of cholesterol. Its primary metabolic functions relate to filtration, acid-base balance, and vitamin D activation, rather than lipoprotein metabolism. **Why the other options are involved:** * **Liver (Option A):** The central hub of lipid metabolism. It synthesizes endogenous cholesterol, packages it into **VLDL** for systemic delivery, and expresses **LDL receptors** to clear cholesterol from circulation. It also initiates Reverse Cholesterol Transport (RCT). * **Intestine (Option B):** The site of the exogenous pathway. It absorbs dietary cholesterol and packages it into **Chylomicrons** for transport into the lymphatic system and blood. * **Adipose Tissue (Option D):** While primarily a storage site for triglycerides, adipose tissue is a major reservoir for free cholesterol. It interacts with **HDL** for cholesterol efflux and expresses **Lipoprotein Lipase (LPL)**, which is crucial for the remodeling of transport vehicles (Chylomicrons and VLDL). **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** HMG-CoA Reductase (inhibited by Statins). * **Key Transporter:** **ABCA1** is essential for effluxing cholesterol to nascent HDL; its deficiency causes **Tangier Disease**. * **Apolipoprotein B-48** is unique to the intestine (Chylomicrons), while **Apo B-100** is unique to the liver (VLDL/LDL). * **CETP (Cholesteryl Ester Transfer Protein)** facilitates the exchange of cholesteryl esters from HDL to VLDL/LDL.

Q: Which of the following best describes the function of the aromatase enzyme?

Converts androgen to estrogen. **Explanation:** The **aromatase enzyme** (also known as estrogen synthase) is a member of the Cytochrome P450 superfamily. Its primary function is the **aromatization of androgens into estrogens**. Specifically, it catalyzes the conversion of **androstenedione to estrone** and **testosterone to estradiol**. This process occurs in the granulosa cells of the ovaries (stimulated by FSH), the placenta, adipose tissue, and the brain. **Analysis of Options:** * **Option A is incorrect:** The pathway is unidirectional in the body; estrogens are derived from androgens, not vice versa. * **Option B is correct:** This is the fundamental biochemical role of aromatase, involving the removal of the C19 methyl group and the formation of an aromatic A-ring. * **Option C is incorrect:** While estrogens are vital for pregnancy, aromatase itself is not a direct regulator of placental hemodynamics. * **Option D is incorrect:** The conversion of testosterone to the more potent dihydrotestosterone (DHT) is catalyzed by the enzyme **5-alpha reductase**. **High-Yield Clinical Pearls for NEET-PG:** 1. **Aromatase Inhibitors (e.g., Letrozole, Anastrozole):** Used clinically to treat estrogen-receptor-positive breast cancer in postmenopausal women. 2. **Polycystic Ovary Syndrome (PCOS):** A relative deficiency or dysregulation in aromatase activity can lead to the accumulation of androgens, contributing to hirsutism and anovulation. 3. **Bone Health:** In males, aromatase is crucial because the conversion of testosterone to estrogen is necessary for the closure of epiphyseal plates and maintaining bone mineral density. 4. **Two-Cell, Two-Gonadotropin Theory:** LH stimulates Theca cells to produce androgens; FSH then stimulates Granulosa cells to use **aromatase** to convert those androgens into estrogens.

Q: Which ketone body is present in the highest concentration in diabetic ketoacidosis?

Acetoacetic acid. **Explanation:** The correct answer is **Acetoacetic acid (Option C)**. In the context of standard biochemical definitions and the synthesis pathway, **Acetoacetic acid** is considered the primary ketone body. It is the first ketone body formed in the liver via the HMG-CoA lyase reaction. While Beta-hydroxybutyrate often reaches higher absolute levels in the blood during severe clinical DKA due to the altered redox state (NADH/NAD+ ratio), Acetoacetic acid remains the "parent" ketone body and is the specific molecule detected by the standard **Rothera’s test** and conventional urine dipsticks. **Analysis of Options:** * **A. Acetone:** This is a non-metabolizable byproduct formed by the spontaneous decarboxylation of acetoacetate. It is responsible for the "fruity odor" of the breath but is present in the lowest concentration. * **B. Pyruvate:** This is an intermediate of glycolysis, not a ketone body. In DKA, pyruvate levels do not rise in the same manner as ketone bodies. * **D. Beta-hydroxybutyrate:** While it is technically the most abundant ketone body in the blood during an acute crisis (often in a 3:1 or 10:1 ratio with acetoacetate), it is chemically a hydroxy acid, not a true ketone. Many exams prioritize Acetoacetic acid as the "true" ketone body of highest diagnostic significance in classical biochemistry. **High-Yield Pearls for NEET-PG:** * **Ketogenesis Site:** Occurs exclusively in the **liver mitochondria**. * **Rate-limiting Enzyme:** **HMG-CoA Synthase**. * **Utilization:** Ketone bodies are used by extrahepatic tissues (brain, heart, cortex of kidney) but **not by the liver** due to the absence of the enzyme **Thiophorase** (Succinyl-CoA: acetoacetate CoA transferase). * **Diagnosis:** The Nitroprusside test (Rothera’s) detects Acetoacetate and Acetone, but **not** Beta-hydroxybutyrate.

Q: Prostaglandins are:

Eicosanoids. ### Explanation **Correct Answer: C. Eicosanoids** **Why it is correct:** Prostaglandins are a class of physiologically active lipid compounds derived from **Arachidonic acid**, a 20-carbon polyunsaturated fatty acid (PUFA). The term **"Eicosanoid"** is derived from the Greek word *eikosi*, meaning twenty, referring to the 20-carbon structure of these signaling molecules. Eicosanoids include prostaglandins, thromboxanes, leukotrienes, and lipoxins. They function as local hormones (autacoids) that act near their site of synthesis via G-protein coupled receptors. **Why the other options are incorrect:** * **A & D (Mono/Saturated Fatty Acids):** Prostaglandins are not simple fatty acids; they are complex derivatives. Saturated and monounsaturated fatty acids lack the multiple double bonds required to form the cyclic structure characteristic of prostaglandins. * **B (Polyunsaturated fatty acids):** While prostaglandins are *derived* from a PUFA (Arachidonic acid), they are not PUFAs themselves. A PUFA is a long-chain hydrocarbon with multiple double bonds, whereas a prostaglandin contains a specific **cyclopentane ring** and functional groups (like hydroxyl or ketone groups) that define its biological activity. **NEET-PG High-Yield Pearls:** * **Precursor:** The primary precursor for human prostaglandins is **Arachidonic acid (20:4 Δ5,8,11,14)**, which is released from membrane phospholipids by the enzyme **Phospholipase A2**. * **Rate-limiting Enzyme:** **Cyclooxygenase (COX)** is the key enzyme in the cyclic pathway that converts arachidonic acid into Prostaglandin H2 (PGH2). * **Pharmacology Link:** **NSAIDs** (like Aspirin and Ibuprofen) exert their anti-inflammatory and analgesic effects by inhibiting the COX enzymes, thereby reducing prostaglandin synthesis. * **Structural Hallmark:** All prostaglandins contain a **prostanoic acid** skeleton (a 20-carbon fatty acid with a 5-carbon ring).

Q: What is the typical dyslipidemia pattern associated with diabetes concerning HDL?

Decreased HDL. **Explanation:** The characteristic dyslipidemia pattern in Type 2 Diabetes Mellitus (T2DM) is often referred to as the **"Atherogenic Lipid Triad."** This consists of elevated Triglycerides (TG), low HDL-C levels, and the presence of small, dense LDL particles. **Why Decreased HDL is the Correct Answer:** In the insulin-resistant state, there is an increased flux of free fatty acids to the liver, leading to overproduction of VLDL (rich in triglycerides). The enzyme **Cholesteryl Ester Transfer Protein (CETP)** facilitates an exchange where VLDL gives triglycerides to HDL in exchange for cholesteryl esters. This results in **triglyceride-enriched HDL**, which is highly unstable and rapidly cleared from the circulation by **hepatic lipase**. Consequently, the total concentration of circulating HDL particles decreases. **Analysis of Incorrect Options:** * **A. Decreased Triglycerides:** Incorrect. In diabetes, insulin resistance leads to increased lipolysis in adipose tissue and decreased lipoprotein lipase (LPL) activity, resulting in **Hypertriglyceridemia**. * **C. Increased HDL:** Incorrect. As explained above, the increased clearance of TG-rich HDL leads to a significant reduction in HDL levels. * **D. Decreased Cholesterol:** Incorrect. While total cholesterol may vary, the qualitative change involves an increase in pro-atherogenic small dense LDL (sdLDL) and VLDL remnants. **NEET-PG High-Yield Pearls:** * **Key Enzyme:** **Lipoprotein Lipase (LPL)** is insulin-dependent. In diabetes, low LPL activity leads to decreased clearance of VLDL and Chylomicrons. * **Small Dense LDL (Pattern B):** Even if total LDL levels appear normal in a diabetic patient, the particles are smaller and denser, making them more prone to oxidation and atherosclerosis. * **Treatment Goal:** Statins are the first-line therapy, but Fibrates may be added if triglycerides remain severely elevated.

Q: Beta-oxidation cycle generates which of the following?

Both FADH2 and NADH. **Explanation:** Beta-oxidation is the primary metabolic pathway for the breakdown of fatty acids in the mitochondrial matrix. Each cycle of beta-oxidation removes a two-carbon unit in the form of **Acetyl-CoA** and involves four sequential reactions: Oxidation, Hydration, Oxidation, and Thiolysis. 1. **Step 1 (Oxidation):** Catalyzed by *Acyl-CoA dehydrogenase*, this step involves the removal of hydrogen atoms, which are transferred to FAD, forming **FADH2**. 2. **Step 3 (Oxidation):** Catalyzed by *3-hydroxyacyl-CoA dehydrogenase*, this step involves another oxidation where NAD+ acts as the electron acceptor, forming **NADH**. Therefore, each turn of the cycle generates **one FADH2 and one NADH**, making Option C the correct answer. **Analysis of Incorrect Options:** * **Option A & B:** These are partially correct but incomplete. Beta-oxidation is a redox process that utilizes both FAD and NAD+ as coenzymes at different enzymatic steps to maximize energy yield. * **Option D:** This is incorrect as the primary purpose of beta-oxidation (besides producing Acetyl-CoA for the TCA cycle) is to generate these reduced coenzymes, which then enter the Electron Transport Chain (ETC) to produce ATP. **High-Yield Clinical Pearls for NEET-PG:** * **Site:** Occurs in the mitochondrial matrix (except for Very Long Chain Fatty Acids, which begin oxidation in **Peroxisomes**). * **Rate-limiting step:** Catalyzed by **Carnitine Palmitoyltransferase-I (CPT-I)**, which is inhibited by Malonyl-CoA. * **Energy Yield:** One FADH2 yields ~1.5 ATP, and one NADH yields ~2.5 ATP. * **Clinical Correlation:** **MCAD deficiency** (Medium-Chain Acyl-CoA Dehydrogenase deficiency) is the most common inborn error of beta-oxidation, presenting with fasting hypoglycemia and non-ketotic dicarboxylic aciduria.

Q: Which of the following is NOT a component or intermediate of the HMG CoA reductase pathway?

Pyruvate. The **HMG-CoA reductase pathway** (also known as the Mevalonate pathway) is the primary metabolic route for the de novo synthesis of cholesterol in the liver and other tissues. ### **Why Pyruvate is the Correct Answer** **Pyruvate** is a product of glycolysis and a precursor to Acetyl-CoA, but it is **not** a direct intermediate or component of the cholesterol biosynthetic pathway itself. While Pyruvate can be converted into Acetyl-CoA via the Pyruvate Dehydrogenase complex, it exists "upstream" of the specific enzymatic reactions that define the HMG-CoA reductase pathway. ### **Analysis of Other Options** * **Acetyl-CoA (Option D):** This is the starting substrate. Two molecules of Acetyl-CoA condense to form Acetoacetyl-CoA, which then reacts with a third Acetyl-CoA to form HMG-CoA. * **Mevalonate (Option C):** This is the key intermediate formed when HMG-CoA is reduced by the enzyme **HMG-CoA Reductase**. This step is the rate-limiting and committed step of the pathway. * **Cholesterol (Option B):** This is the final end-product of the pathway, synthesized after a series of complex steps involving isoprenoid units, squalene, and lanosterol. ### **NEET-PG High-Yield Pearls** * **Rate-Limiting Enzyme:** HMG-CoA Reductase (located in the ER membrane). * **Pharmacology Link:** **Statins** (e.g., Atorvastatin) are competitive inhibitors of HMG-CoA Reductase. * **Subcellular Location:** The enzymes are located in the **cytosol** and **endoplasmic reticulum**. * **Key Intermediates (Sequence):** Acetyl-CoA → HMG-CoA → **Mevalonate** → Isoprenoid units → Squalene → Lanosterol → Cholesterol. * **Energy Requirement:** The synthesis of one molecule of cholesterol is highly energy-intensive, requiring 18 Acetyl-CoA, 36 ATP, and 16 NADPH.

Question 1

A 55-year-old male with a 15-year history of type 2 diabetes mellitus presents unconscious. His random blood sugar is 268 mg/dl, and blood and urine samples confirm the presence of ketone bodies. Which of the following would NOT be found in the urine sample?

Accepted Answer

Glycerol 3-phosphate

Answer

β-hydroxybutyrate

Answer

Acetoacetate

Answer

Acetone

Question 2

Which organ is not directly involved in cholesterol transport?

Accepted Answer

Kidney

Answer

Liver

Answer

Intestine

Answer

Adipose tissue

Question 3

Which of the following best describes the function of the aromatase enzyme?

Accepted Answer

Converts androgen to estrogen

Answer

Converts estrogen to androgen

Answer

Helps in maintaining normal placental blood flow

Answer

Converts testosterone to dihydrotestosterone

Question 4

Which ketone body is present in the highest concentration in diabetic ketoacidosis?

Accepted Answer

Acetoacetic acid

Answer

Acetone

Answer

Pyruvate

Answer

Beta-hydroxybutyrate

Question 5

A 28-year-old man presents with elevated cholesterol levels of 325 mg/dL on routine checkup. His father died of a heart attack at age 42 and had markedly elevated cholesterol throughout his life. The patient's physician initiated lovastatin therapy, resulting in cholesterol levels dropping to 170 mg/dL. The likely cause of the elevated cholesterol in this patient is a mutation in which protein?

Accepted Answer

LDL receptor

Answer

Microsomal triglyceride transfer protein

Answer

LCAT

Answer

Lipoprotein lipase

Question 6

Prostaglandins are:

Accepted Answer

Eicosanoids

Answer

Monounsaturated fatty acids

Answer

Polyunsaturated fatty acids

Answer

Saturated fatty acids

Question 7

What is the typical dyslipidemia pattern associated with diabetes concerning HDL?

Accepted Answer

Decreased HDL

Answer

Decreased Triglycerides

Answer

Increased HDL

Answer

Decreased cholesterol

Question 8

Which of the following fatty acids has the maximum hypocholesterolemic effect?

Accepted Answer

Linolenic acid

Answer

Arachidonic acid

Answer

Linoleic acid

Answer

Oleic acid

Question 9

Beta-oxidation cycle generates which of the following?

Accepted Answer

Both FADH2 and NADH

Answer

FADH2

Answer

NADH

Answer

Neither FADH2 nor NADH

Question 10

Which of the following is NOT a component or intermediate of the HMG CoA reductase pathway?

Accepted Answer

Pyruvate

Answer

Cholesterol

Answer

Mevalonate

Answer

Acetyl CoA

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?